|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 6,500,814
Patent Overview
U.S. Patent 6,500,814, issued on December 31, 2002, to Pharmacia & Upjohn, covers a composition and method for treating cardiovascular diseases, specifically broadening the use of certain phosphodiesterase inhibitors. The patent primarily claims a class of compounds, pharmaceutical compositions containing these compounds, and methods for their use in treating diseases such as congestive heart failure and erectile dysfunction.
Primary Claim Summary
The core claim (Claim 1) defines a class of compounds: phosphodiesterase inhibitors with specific structural features. It covers molecules with a substituted phenylmethyl group linked to a heterocyclic core, where the substitution pattern is detailed to ensure selectivity for phosphodiesterase type 5 (PDE5). The claim extends to pharmaceutical formulations and methods of administering these compounds to treat specific conditions.
Subsequent claims specify variations on Claim 1, including specific chemical substitutions, dosing regimens, and formulation types. Claims also include methods of treating cardiovascular-related diseases using these compounds.
Claim Scope and Limitations
| Aspect |
Details |
Implication |
| Molecular class |
Phosphodiesterase inhibitors with specific heterocyclic core and phenylmethyl substituents |
Limited to compounds fitting specified structural features, excluding broad generic PDE5 inhibitors outside this framework |
| Therapeutic indications |
Congestive heart failure, erectile dysfunction |
Focused targeting of PDE5-mediated conditions, pre-dating or overlapping with sildenafil’s scope |
| Formulations |
Pharmaceutical compositions including inhibitors, including oral and injectable forms |
Patent covers various administration methods, broadening potential patent protection for formulations |
| Method claims |
Treating conditions by administering these compounds |
Protects healthcare methods, potentially shielding off-label uses within patent scope |
Patent Landscape Analysis
-
Prior Art Context
The patent builds upon earlier PDE5 inhibitors, especially sildenafil (U.S. Patent 4,863,734, issued in 1989), which was approved in 1998 for erectile dysfunction. U.S. 6,500,814 expands on structural classes, focusing on specific heterocyclic derivatives, aiming to improve selectivity and reduce side effects.
-
Related Patents and Competitors
The patent landscape includes subsequent filings covering PDE5 inhibitors, such as tadalafil (U.S. Patent 5,561,144) and vardenafil, with overlapping claims on methods and formulations. Companies like Lilly, GSK, and Bayer have patents in related classes, creating a crowded patent field.
-
Legal Status and Litigation
As of 2023, U.S. 6,500,814 remains enforceable with no significant litigations recorded. Yet, patent challenges overlap with later filings on formulations and methods, especially around other PDE5 inhibitors.
-
Geographic Patent Coverage
The patent family spans major markets, including Europe (via EPO applications), Japan, and Canada, with enforceable rights differing per jurisdiction. The U.S. patent forms a core component of global patent strategies.
-
Expiration Date
The patent was issued in 2002, with a 20-year term extending to 2022, assuming maintenance fees paid timely. Any lapse or non-payment could open pathways for generics.
Competitive and Innovation Trends
Post-2002, innovation shifted toward targeted PDE5 inhibitors with improved pharmacokinetics and side-effect profiles. Patent filings have often focused on secondary indications, combination therapies, and delivery methods, diverging from the compound class patented in 6,500,814.
Implications for Licensing and Development
The patent's expiration or licensing potential enables generic manufacturers to launch alternatives. Current patent landscape analyses highlight active patenting around PDE5 inhibitors' formulations and methods, indicating ongoing innovation and potential legal hurdles.
Key Takeaways
- U.S. Patent 6,500,814 claims a specific class of PDE5 inhibitors with particular structural features and their medical uses.
- The scope is concentrated on compounds, formulations, and methods for treating erectile dysfunction and cardiovascular conditions.
- Its patent landscape is characterized by overlapping claims from major pharmaceutical entities developing similar PDE5 inhibitors, with a crowded patent environment.
- The patent's expiration date in 2022 may open opportunities for generics, but ongoing patent protections on formulations and methods could pose barriers.
- The patent's niche position and overlapping innovations suggest careful clearance studies are necessary for new entrants.
FAQs
-
What structural features does U.S. Patent 6,500,814 specify for PDE5 inhibitors?
It claims compounds with a heterocyclic core linked to a phenylmethyl group, with specific substitutions that influence PDE5 selectivity.
-
Which diseases does the patent primarily aim to treat?
Congestive heart failure and erectile dysfunction are the main indications.
-
How does this patent relate to sildenafil’s patent coverage?
It extends PDE5 inhibitor patent claims but is narrower in chemical scope, focusing on certain heterocyclic derivatives.
-
Can this patent be licensed or challenged now?
Given its expiration in 2022, licensing may be pertinent for certain formulations or method claims, but legal challenges depend on ongoing patent rights in related areas.
-
What strategic considerations should companies pursue?
Assess overlapping patent rights, consider timing for generic launches, and explore formulations or indications beyond the claims to avoid infringement or develop around the patent.
References
- U.S. Patent 6,500,814.
- U.S. Patent 4,863,734 (Sildenafil).
- EPO patent publications related to PDE5 inhibitors.
- FDA approval records for sildenafil and related drugs.
More… ↓
⤷ Start Trial
|
